Skip to main content
FDA grants orphan status to Fountain's hyper IgE syndrome drug
10/11/2017

The FDA gave orphan drug designation to Fountain Biopharma's FB825, an anti-CemX anti-allergic monoclonal antibody being developed as a treatment for patients with hyper IgE syndrome.

Full Story: